Implant Trade Secrets Are Not Protectable Due to Disclosure in Patents

Why It Matters

The ruling clarifies that patent filings can extinguish trade‑secret protection, forcing companies to rethink IP strategies and confidentiality practices.

Key Takeaways

• Patent disclosure can render related trade secrets unprotectable
• Federal Circuit applied CUTSA’s “generally known” standard
• Improper confidentiality markings nullify trade‑secret claims
• Companies must segregate patent and secret information
• Court affirmed counterfeiting claim denial, limiting damages

Pulse Analysis

The Federal Circuit’s decision in International Medical Devices v. Cornell underscores a pivotal intersection between patent law and trade‑secret protection. Under California’s Uniform Trade Secrets Act, information that becomes “generally known”—including details published in a patent—fails the secrecy requirement. By treating the patented implant designs as public disclosures, the court eliminated IMD’s trade‑secret claims, reinforcing the principle that patents, by nature, sacrifice confidentiality for exclusive rights. This outcome aligns with longstanding jurisprudence that trade secrets must remain hidden to retain legal protection.

For medical‑device manufacturers, the ruling sends a clear warning: filing a patent without rigorous internal controls can jeopardize parallel trade‑secret assets. The court’s emphasis on proper labeling highlights the necessity of robust confidentiality protocols. Companies should institute distinct data‑segregation practices, ensuring that patent‑related disclosures are isolated from proprietary processes that rely on secrecy. Failure to do so not only risks losing trade‑secret claims but also weakens bargaining positions in litigation, as seen when IMD’s breach‑of‑contract and patent‑invalidity arguments were also reversed.

The broader industry implication is a shift toward integrated IP management. Firms must balance the breadth of patent protection with the depth of trade‑secret safeguards, often opting for strategic timing—securing patents first, then tightening internal confidentiality measures. Legal teams should conduct regular audits of marked confidential documents and train staff on labeling standards. As courts continue to scrutinize the overlap between disclosed patents and alleged secrets, proactive IP governance will become a competitive advantage, preserving both innovation incentives and enforceable trade‑secret rights.